Evidence map›Paper›PMID 26729104›Full record

GuidelineInternational journal of molecular sciences2015

Pharmacotherapy Treatment Options for Insomnia: A Primer for Clinicians.

Gregory M Asnis, Manju Thomas, Margaret A Henderson

Open access · goldAbstract readPractice GuidelineReview
PubMed Full text at PMC Publisher
In one paragraph

Guideline in International journal of molecular sciences, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed, 3 pooled it
6.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 3 syntheses or guidelines pooled it, 99 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. A Closer Look at Yoga Nidra: Sleep Lab Protocol.International journal of yoga therapy · 2021
    Trial
  11. Efficacy and safety of esmirtazapine in adult outpatients with chronic primary insomnia: a randomized, double-blind placebo-controlled study and open-label extension.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2020
    Trial
  12. Trial
  13. Trial
  14. Trial
  15. Understanding the Use of Acupuncture for Insomnia Among Cancer Survivors: A Qualitative Study.Journal of alternative and complementary medicine (New York, N.Y.)
    Trial
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Gregory M AsnisAlbert Einstein College of Medicine/Montefiore Medical Center, Department of Psychiatry & Behavioral Science, Bronx, NY 10467, USA. asnisarts@aol.com.
Manju ThomasThe Anxiety and Depression Clinic, Bronx, NY 10570, USA. manju.thomas3@gmail.com.
Margaret A HendersonThe Anxiety and Depression Clinic, Bronx, NY 10570, USA. mahg96@aol.com.
Center for Anxiety and Depression · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Insomnia is a prevalent disorder with deleterious effects such as decreased quality of life, and a predisposition to a number of psychiatric disorders. Fortunately, numerous approved hypnotic treatments are available. This report reviews the state of the art of pharmacotherapy with a reference to cognitive behavioral therapy for insomnia (CBT-I) as well. It provides the clinician with a guide to all the Food and Drug Administration (FDA) approved hypnotics (benzodiazepines, nonbenzodiazepines, ramelteon, low dose sinequan, and suvorexant) including potential side effects. Frequently, chronic insomnia lasts longer than 2 years. Cognizant of this and as a result of longer-term studies, the FDA has approved all hypnotics since 2005 without restricting the duration of use. Our manuscript also reviews off-label hypnotics (sedating antidepressants, atypical antipsychotics, anticonvulsants and antihistamines) which in reality, are more often prescribed than approved hypnotics. The choice of which hypnotic to choose is discussed partially being based on which segment of sleep is disturbed and whether co-morbid illnesses exist. Lastly, we discuss recent label changes required by the FDA inserting a warning about "sleep-related complex behaviors", e.g., sleep-driving for all hypnotics. In addition, we discuss FDA mandated dose reductions for most zolpidem preparations in women due to high zolpidem levels in the morning hours potentially causing daytime carry-over effects.

Indexed as

AdultAgedAged, 80 and overFemaleHumansHypnotics and SedativesMaleMiddle AgedSleep Initiation and Maintenance DisordersUnited StatesUnited States Food and Drug AdministrationYoung AdultHypnotics and Sedativesguidelineshypnoticsinsomniatreatment options

Identifiers

PMID26729104
PMCPMC4730295
OpenAlexW2221723423

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.